Organization (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	9 Months Ended		12 Months Ended
	Oct. 02, 2026	Oct. 31, 2026	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2023	Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued			1,501,984			1,285,835
Proceeds from issuance of common stock			$ 255	$ 131
Common stock, shares authorized			89,000,000			72,213,000
Common Stock, Par or Stated Value Per Share			$ 0.0001			$ 0.0001
Cash, cash equivalents and marketable securities			$ 78,200
Accumulated deficit			$ (136,806)			$ (94,259)
Collaborative Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration revenue					$ 41,900
Lilly [Member] | Lilly Collaboration Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received					$ 55,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse Stock Split	1-for-3.8649
IPO [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued		9,539,237
Sale of stock, price per share		$ 14
Proceeds from issuance of common stock		$ 119,000
Stock issued during period, shares, conversion of convertible securities		17,742,217
Common stock, shares authorized		225,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001
Preferred stock, shares authorized		25,000,000
Preferred stock, par value		$ 0.0001
Over-Allotment Option [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of Shares Issued in Transaction		1,205,903